Literature DB >> 25582069

The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells.

Yang Cao1,2, Guang Yang1,2, Zachary R Hunter1,3,4, Xia Liu1,2, Lian Xu1, Jie Chen1, Nickolas Tsakmaklis1, Evdoxia Hatjiharissi3,4, Sandra Kanan1, Matthew S Davids1,2, Jorge J Castillo1,2, Steven P Treon5,6.   

Abstract

Entities:  

Keywords:  ABT-199; BCL2; CXCR4; Ibrutinib; Waldenström macroglobulinemia

Mesh：

Substances：

Year:  2015        PMID： 25582069     DOI： 10.1111/bjh.13278

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  32 in total

Review 1.  BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis.

Authors:  Christopher J Gibson; Matthew S Davids
Journal:  Clin Cancer Res       Date:  2015-11-15       Impact factor: 12.531

Review 2.  Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.

Authors:  Gilad Itchaki; Jennifer R Brown
Journal:  Ther Adv Hematol       Date:  2017-11-28

3.  Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.

Authors:  C Baer; F Dicker; W Kern; T Haferlach; C Haferlach
Journal:  Leukemia       Date:  2016-11-14       Impact factor: 11.528

Review 4.  Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.

Authors:  Saurabh Zanwar; Jithma Prasad Abeykoon; Prashant Kapoor
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

5.  Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.

Authors:  Fabiola Cervantes-Gomez; Betty Lamothe; Jennifer A Woyach; William G Wierda; Michael J Keating; Kumudha Balakrishnan; Varsha Gandhi
Journal:  Clin Cancer Res       Date:  2015-03-31       Impact factor: 12.531

Review 6.  Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.

Authors:  Joel D Leverson; Deepak Sampath; Andrew J Souers; Saul H Rosenberg; Wayne J Fairbrother; Martine Amiot; Marina Konopleva; Anthony Letai
Journal:  Cancer Discov       Date:  2017-11-16       Impact factor: 39.397

Review 7.  Venetoclax: First Global Approval.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2016-06       Impact factor: 9.546

Review 8.  Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.

Authors:  Andrew Aw; Jennifer R Brown
Journal:  Drugs Aging       Date:  2017-07       Impact factor: 3.923

9.  Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.

Authors:  Zachary R Hunter; Lian Xu; Guang Yang; Nicholas Tsakmaklis; Josephine M Vos; Xia Liu; Jie Chen; Robert J Manning; Jiaji G Chen; Philip Brodsky; Christopher J Patterson; Joshua Gustine; Toni Dubeau; Jorge J Castillo; Kenneth C Anderson; Nikhil M Munshi; Steven P Treon
Journal:  Blood       Date:  2016-06-14       Impact factor: 22.113

Review 10.  Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.

Authors:  Lesley J Scott
Journal:  Target Oncol       Date:  2019-10       Impact factor: 4.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.